Literature DB >> 31550348

An Infectious Diseases Perspective on Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children.

Jillian M Cotter1, Maribeth R Nicholson2, Larry K Kociolek3.   

Abstract

Fecal microbiota transplantation (FMT) is efficacious for treatment of recurrent Clostridioides difficile infections (rCDIs). Pediatric experience with FMT for rCDIs is increasing, particularly at large centers. While retrospective studies suggest that FMT is generally safe in the short term, particularly in immunocompetent patients and with rigorous donor screening, additional large prospective studies are needed. This particularly includes those at high risk for infectious complications, such as immunocompromised hosts. Further, long-term implications of altering the intestinal microbiome with FMT are not well understood. The role of FMT in children, particularly in high-risk patients, will require continual reexamination with future availability of pediatric safety and efficacy data. This review summarizes key points for infectious diseases physicians to consider when evaluating a child for FMT.
© The Author(s) 2019. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Clostridioides difficilezzm321990 ; zzm321990 Clostridium difficilezzm321990 ; fecal microbiota transplantation; safety; screening

Mesh:

Year:  2019        PMID: 31550348      PMCID: PMC7317149          DOI: 10.1093/jpids/piz062

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  32 in total

1.  Bacteremia as an adverse event of fecal microbiota transplantation in a patient with Crohn's disease and recurrent Clostridium difficile infection.

Authors:  Rodrigo Quera; Ricardo Espinoza; Camila Estay; Daniela Rivera
Journal:  J Crohns Colitis       Date:  2013-11-01       Impact factor: 9.071

2.  Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial.

Authors:  Christine H Lee; Theodore Steiner; Elaine O Petrof; Marek Smieja; Diane Roscoe; Anouf Nematallah; J Scott Weese; Stephen Collins; Paul Moayyedi; Mark Crowther; Mark J Ropeleski; Padman Jayaratne; David Higgins; Yingfu Li; Neil V Rau; Peter T Kim
Journal:  JAMA       Date:  2016-01-12       Impact factor: 56.272

3.  Strategies for Optimizing the Diagnostic Predictive Value of Clostridium difficile Molecular Diagnostics.

Authors:  Larry K Kociolek
Journal:  J Clin Microbiol       Date:  2017-03-08       Impact factor: 5.948

4.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).

Authors:  L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

Review 5.  Breakthroughs in the treatment and prevention of Clostridium difficile infection.

Authors:  Larry K Kociolek; Dale N Gerding
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-02-10       Impact factor: 46.802

6.  Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection and Other Conditions in Children: A Joint Position Paper From the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Zev H Davidovics; Sonia Michail; Maribeth R Nicholson; Larry K Kociolek; Nikhil Pai; Richard Hansen; Tobias Schwerd; Aldo Maspons; Raanan Shamir; Hania Szajewska; Nikhil Thapar; Tim de Meij; Alexis Mosca; Yvan Vandenplas; Stacy A Kahn; Richard Kellermayer
Journal:  J Pediatr Gastroenterol Nutr       Date:  2019-01       Impact factor: 2.839

7.  Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

Authors:  Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

8.  Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study.

Authors:  Robert Orenstein; Erik Dubberke; Robert Hardi; Arnab Ray; Kathleen Mullane; Darrell S Pardi; Mayur S Ramesh
Journal:  Clin Infect Dis       Date:  2015-11-12       Impact factor: 9.079

9.  An Intragastric Fecal Microbiota Transplantation Program for Treatment of Recurrent Clostridium difficile in Children is Efficacious, Safe, and Inexpensive.

Authors:  David E Brumbaugh; Edwin F De Zoeten; Amy Pyo-Twist; Sara Fidanza; Shannon Hughes; Susan A Dolan; Jason Child; Samuel R Dominguez
Journal:  J Pediatr       Date:  2017-12-01       Impact factor: 4.406

Review 10.  Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.

Authors:  M N Quraishi; M Widlak; N Bhala; D Moore; M Price; N Sharma; T H Iqbal
Journal:  Aliment Pharmacol Ther       Date:  2017-07-14       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.